Literature DB >> 27326339

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors.

Bin Zhao1, Yixuan Li1, Pan Xu1, Yang Dai1, Cheng Luo1, Yiming Sun1, Jing Ai1, Meiyu Geng1, Wenhu Duan1.   

Abstract

Fibroblast growth factor receptors (FGFRs) are important targets for cancer therapy. Herein, we describe the design, synthesis, and biological evaluation of a novel series of 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors. On the basis of its excellent in vitro potency and favorable pharmacokinetic properties, compound 7n was selected for in vivo evaluation and showed significant antitumor activity in a FGFR1-driven H1581 xenograft model. These results indicated that 7n would be a promising candidate for further drug development.

Entities:  

Keywords:  Cancer; FGFR; inhibitor; pyrazolo[3,4-b]pyridine

Year:  2016        PMID: 27326339      PMCID: PMC4904267          DOI: 10.1021/acsmedchemlett.6b00066

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

Review 1.  Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.

Authors:  Han Kiat Ho; Angie Hui Ling Yeo; Tse Siang Kang; Boon Tin Chua
Journal:  Drug Discov Today       Date:  2013-08-06       Impact factor: 7.851

Review 2.  Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

Authors:  Edward P Carter; Abbie E Fearon; Richard P Grose
Journal:  Trends Cell Biol       Date:  2014-11-29       Impact factor: 20.808

3.  AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Authors:  Paul R Gavine; Lorraine Mooney; Elaine Kilgour; Andrew P Thomas; Katherine Al-Kadhimi; Sarah Beck; Claire Rooney; Tanya Coleman; Dawn Baker; Martine J Mellor; A Nigel Brooks; Teresa Klinowska
Journal:  Cancer Res       Date:  2012-02-27       Impact factor: 12.701

Review 4.  Targeting the fibroblast growth factor receptors for the treatment of cancer.

Authors:  Steven M Lemieux; M Kyle Hadden
Journal:  Anticancer Agents Med Chem       Date:  2013-06       Impact factor: 2.505

Review 5.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

Review 6.  Targeting FGFR Signaling in Cancer.

Authors:  Mehdi Touat; Ecaterina Ileana; Sophie Postel-Vinay; Fabrice André; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2015-06-15       Impact factor: 12.531

Review 7.  The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.

Authors:  Roberto Ronca; Arianna Giacomini; Marco Rusnati; Marco Presta
Journal:  Expert Opin Ther Targets       Date:  2015-06-30       Impact factor: 6.902

Review 8.  Toxicity of targeted therapy in non-small-cell lung cancer management.

Authors:  Serena Ricciardi; Silverio Tomao; Filippo de Marinis
Journal:  Clin Lung Cancer       Date:  2009-01       Impact factor: 4.785

Review 9.  De-regulated FGF receptors as therapeutic targets in cancer.

Authors:  Victoria Knights; Simon J Cook
Journal:  Pharmacol Ther       Date:  2009-10-27       Impact factor: 12.310

10.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

Authors:  M Mohammadi; S Froum; J M Hamby; M C Schroeder; R L Panek; G H Lu; A V Eliseenkova; D Green; J Schlessinger; S R Hubbard
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

View more
  6 in total

1.  Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.

Authors:  Sven Verdonck; Szu-Yuan Pu; Fiona J Sorrell; Jon M Elkins; Mathy Froeyen; Ling-Jie Gao; Laura I Prugar; Danielle E Dorosky; Jennifer M Brannan; Rina Barouch-Bentov; Stefan Knapp; John M Dye; Piet Herdewijn; Shirit Einav; Steven De Jonghe
Journal:  J Med Chem       Date:  2019-06-12       Impact factor: 7.446

2.  Synthesis and biological evaluation of indazole derivatives as anti-cancer agents.

Authors:  Wei Wei; Zhihao Liu; Xiuli Wu; Cailing Gan; Xingping Su; Hongyao Liu; Hanyun Que; Qianyu Zhang; Qiang Xue; Lin Yue; Luoting Yu; Tinghong Ye
Journal:  RSC Adv       Date:  2021-04-27       Impact factor: 4.036

3.  Synthesis of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines via one-pot sequential Suzuki-Miyaura coupling.

Authors:  Vibha Tandon; Parthasarathi Das; S Kukreti
Journal:  RSC Adv       Date:  2018-10-11       Impact factor: 3.361

4.  Design, One Pot Synthesis and Molecular Docking Studies of Substituted-1H-Pyrido[2,1-b] Quinazolines as Apoptosis-Inducing Anticancer Agents.

Authors:  Raju Bathula; Shobha Rani Satla; Ramadevi Kyatham; Kiran Gangarapu
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

5.  Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.

Authors:  Zhen Zhang; Dongmei Zhao; Yang Dai; Maosheng Cheng; Meiyu Geng; Jingkang Shen; Yuchi Ma; Jing Ai; Bing Xiong
Journal:  Molecules       Date:  2016-10-23       Impact factor: 4.411

Review 6.  Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.

Authors:  Jia Zheng; Wei Zhang; Linfeng Li; Yi He; Yue Wei; Yongjun Dang; Shenyou Nie; Zufeng Guo
Journal:  Front Chem       Date:  2022-04-14       Impact factor: 5.545

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.